Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-05-28 DOI:10.1016/j.trecan.2025.05.004

John B Haanen

引用次数: 0

Abstract

A recent study published in Nature Medicine shows that adoptive cell therapy using neoantigen-selected tumor-infiltrating lymphocytes (TIL) is feasible in refractory metastatic gastrointestinal (GI) cancers, showing durable responses, especially when combined with anti-PD-1. Despite low tumor mutational burden (TMB), enriched neoantigen-reactive TIL improved objective response rates (ORR), highlighting the role of the tumor microenvironment and supporting further clinical development.

查看原文本刊更多论文

pMMR胃肠道肿瘤伴肿瘤浸润淋巴细胞（TIL）患者的治疗：现实？

最近发表在《自然医学》杂志上的一项研究表明，使用新抗原选择的肿瘤浸润淋巴细胞（TIL）的过继细胞治疗在难治性转移性胃肠道（GI）癌症中是可行的，表现出持久的反应，特别是与抗pd -1联合使用时。尽管肿瘤突变负担（TMB）较低，但富集的新抗原反应性TIL提高了客观反应率（ORR），突出了肿瘤微环境的作用，并支持进一步的临床发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.